Benefit – Talk Bio

Survival Benefit of Amgen’s Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

1 week ago talkbio0Tagged amgen, Attenuated by (contextual qualifier), bemarituzumab, Benefit, final analysis, FORTITUDE-101, FORTITUDE-102, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Zai Lab

Amgen; bemarituzumab; gastric cancer; Phase 3 trial; overall survival; attenuated benefit; final analysis; FORTITUDE-101; FORTITUDE-102; Zai Lab; Opdivo; nivolumab

Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance

4 weeks ago talkbio0Tagged Benefit, Clinical Trials, competition, Compounders, Direct-to-Consumer, eli lilly, Glucagon-Like Peptide 1, manager, Market, Nordisk, Obesity, Pharmaceutical Services, Wegovy, Zepbound

obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials

Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit

2 months ago talkbio0Tagged asset termination, Benefit, biotech acquisition, Clinical Trials, lack of, Merck, Pandion

Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

2 months ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

2 months ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint

3 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, DAZALS trial, dazucorilant, Phase 2 Clinical Trials, SURVEY.ALSFRSR, Survival

Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

6 months ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.